McKesson's new program helps build bridges.
Drug companies have a new avenue to reach dispersed independent pharmacists, a group that traditionally has stronger ties to local communities than industry or distributors.
McKesson Pharmaceutical has launched a franchising initiative to give independent pharmacists more negotiating power with pharmacy benefits managers (PBMs) and open communication with drug makers.
By joining the Health Mart franchise, independent pharmacy owners are united under a national brand, and can maximize their buying power and share market intelligence.
The franchise also offers drug companies a single avenue into local communities, giving marketers the ability to devise consistent education and promotional programs across franchises that also have a local feel.
Independent pharmacists also want greater interaction with drug makers.
Douglas Hoey, senior vice president and COO of the National Community Pharmacy Association, noted that the organization recently surveyed its members on whether they wanted more interaction with drug sales reps. "Overwhelmingly, the answer was yes," he said.
"The big [pharma] companies tend to ignore the independents," said Tim Canning, vice president of retail marketing for McKesson. "There's no consistent retail execution."
Yet independent pharmacists are often involved not only in selling drugs, but in programs such as clinical-trial recruitment. They can also spot local drug utilization trends that could be beneficial to manufacturers.
Through Health Mart, "the branded manufacturers have a communication vehicle into those pharmacies," said Andy Burtis, vice president of marketing services for McKesson.
Cardinal Health already operates its Medicine Shoppe franchise for independent pharmacists. But McKesson executives say Health Mart requires no sign-up fees or long-term commitments, unlike many other franchises.
A national advertising campaign for Health Mart will focus on the patient-pharmacist relationship, and McKesson is also working with Interbrand on branding efforts.
"They're able to keep their independence but have a collective strength," Burtis said.
He added that 350 pharmacies have already joined Health Mart, and that McKesson aims to have 1,000 stores on board by next year. It hopes to draw members from stores that are already part of its AccessHealth managed care and contracting program.
The increasing dominance of PBMs, as well as new pressures created by Medicare Part D reimbursement, have put pressure on community pharmacists. But even as the landscape has changed, fewer pharmacy schools are providing courses on how to manage a business, according to Hoey.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.